Literature DB >> 28053186

AAV9-NPC1 significantly ameliorates Purkinje cell death and behavioral abnormalities in mouse NPC disease.

Chang Xie1,2, Xue-Min Gong2, Jie Luo1, Bo-Liang Li2, Bao-Liang Song3.   

Abstract

Niemann-Pick type C (NPC) disease is a fatal inherited neurodegenerative disorder caused by loss-of-function mutations in the NPC1 or NPC2 gene. There is no effective way to treat NPC disease. In this study, we used adeno-associated virus (AAV) serotype 9 (AAV9) to deliver a functional NPC1 gene systemically into NPC1-/- mice at postnatal day 4. One single AAV9-NPC1 injection resulted in robust NPC1 expression in various tissues, including brain, heart, and lung. Strikingly, AAV9-mediated NPC1 delivery significantly promoted Purkinje cell survival, restored locomotor activity and coordination, and increased the lifespan of NPC1-/- mice. Our work suggests that AAV-based gene therapy is a promising means to treat NPC disease.
Copyright © 2017 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Niemann-Pick type C disease; Niemann-Pick type C1; adeno-associated virus serotype 9; blood-brain barrier; cholesterol; gene therapy; lysosomal storage diseases

Mesh:

Substances:

Year:  2017        PMID: 28053186      PMCID: PMC5335581          DOI: 10.1194/jlr.M071274

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  40 in total

1.  Niemann-Pick C1 mice, a model of "juvenile Alzheimer's disease", with normal gene expression in neurons and fibrillary astrocytes show long term survival and delayed neurodegeneration.

Authors:  Ivan Borbon; John Totenhagen; Maria Teresa Fiorenza; Sonia Canterini; Wangjing Ke; Theodore Trouard; Robert P Erickson
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors.

Authors:  Michael J Blankinship; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2005-12-19       Impact factor: 11.454

3.  Rescue of neurodegeneration in Niemann-Pick C mice by a prion-promoter-driven Npc1 cDNA transgene.

Authors:  Stacie K Loftus; Robert P Erickson; Steven U Walkley; Mark A Bryant; Arturo Incao; Randall A Heidenreich; William J Pavan
Journal:  Hum Mol Genet       Date:  2002-11-15       Impact factor: 6.150

4.  Correction of a genetic disease in mouse via use of CRISPR-Cas9.

Authors:  Yuxuan Wu; Dan Liang; Yinghua Wang; Meizhu Bai; Wei Tang; Shiming Bao; Zhiqiang Yan; Dangsheng Li; Jinsong Li
Journal:  Cell Stem Cell       Date:  2013-12-05       Impact factor: 24.633

5.  Cholesterol transport through lysosome-peroxisome membrane contacts.

Authors:  Bei-Bei Chu; Ya-Cheng Liao; Wei Qi; Chang Xie; Ximing Du; Jiang Wang; Hongyuan Yang; Hong-Hua Miao; Bo-Liang Li; Bao-Liang Song
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

6.  Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse.

Authors:  Benny Liu; Stephen D Turley; Dennis K Burns; Anna M Miller; Joyce J Repa; John M Dietschy
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

7.  Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells.

Authors:  Lina Abi-Mosleh; Rodney E Infante; Arun Radhakrishnan; Joseph L Goldstein; Michael S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-02       Impact factor: 11.205

8.  Relevance of neuronal and glial NPC1 for synaptic input to cerebellar Purkinje cells.

Authors:  Isabelle Buard; Frank W Pfrieger
Journal:  Mol Cell Neurosci       Date:  2014-06-07       Impact factor: 4.314

9.  Anatomically defined neuron-based rescue of neurodegenerative Niemann-Pick type C disorder.

Authors:  Manuel E Lopez; Andres D Klein; Ubah J Dimbil; Matthew P Scott
Journal:  J Neurosci       Date:  2011-03-23       Impact factor: 6.167

10.  Isolation and characterization of Chinese hamster ovary cell mutants defective in intracellular low density lipoprotein-cholesterol trafficking.

Authors:  K M Cadigan; D M Spillane; T Y Chang
Journal:  J Cell Biol       Date:  1990-02       Impact factor: 10.539

View more
  18 in total

Review 1.  The Extending Spectrum of NPC1-Related Human Disorders: From Niemann-Pick C1 Disease to Obesity.

Authors:  Amel Lamri; Marie Pigeyre; William S Garver; David Meyre
Journal:  Endocr Rev       Date:  2018-04-01       Impact factor: 19.871

2.  Microglia activation in Niemann-Pick disease, type C1 is amendable to therapeutic intervention.

Authors:  Antony Cougnoux; Rebecca A Drummond; Amanda L Collar; James R Iben; Alexander Salman; Harrison Westgarth; Christopher A Wassif; Niamh X Cawley; Nicole Y Farhat; Keiko Ozato; Michail S Lionakis; Forbes D Porter
Journal:  Hum Mol Genet       Date:  2018-06-15       Impact factor: 6.150

3.  Gene Therapy in a Mouse Model of Niemann-Pick Disease Type C1.

Authors:  Yoshie Kurokawa; Hitoshi Osaka; Takeshi Kouga; Eriko Jimbo; Kazuhiro Muramatsu; Sachie Nakamura; Yuki Takayanagi; Tatsushi Onaka; Shin-Ichi Muramatsu; Takanori Yamagata
Journal:  Hum Gene Ther       Date:  2021-02-22       Impact factor: 5.695

Review 4.  Recent neuroimaging, neurophysiological, and neuropathological advances for the understanding of NPC.

Authors:  Alberto Benussi; Maria Sofia Cotelli; Alessandro Padovani; Barbara Borroni
Journal:  F1000Res       Date:  2018-02-15

Review 5.  Clinical and Molecular Features of Early Infantile Niemann Pick Type C Disease.

Authors:  Berna Seker Yilmaz; Julien Baruteau; Ahad A Rahim; Paul Gissen
Journal:  Int J Mol Sci       Date:  2020-07-17       Impact factor: 5.923

6.  Potential Disease-Modifying Effects of Lithium Carbonate in Niemann-Pick Disease, Type C1.

Authors:  Shiqian Han; Huiwen Zhang; Mengni Yi; Xiaoqing Liu; Gustavo H B Maegawa; Yunding Zou; Qijun Wang; Dianqing Wu; Zhijia Ye
Journal:  Front Pharmacol       Date:  2021-06-09       Impact factor: 5.810

7.  Transcriptome of HPβCD-treated Niemann-Pick disease type C1 cells highlights GPNMB as a biomarker for therapeutics.

Authors:  Jorge L Rodriguez-Gil; Laura L Baxter; Dawn E Watkins-Chow; Nicholas L Johnson; Cristin D Davidson; Steven R Carlson; Arturo A Incao; Kerri L Wallom; Nicole Y Farhat; Frances M Platt; Ryan K Dale; Forbes D Porter; William J Pavan
Journal:  Hum Mol Genet       Date:  2021-11-30       Impact factor: 5.121

8.  AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease.

Authors:  Michael P Hughes; Dave A Smith; Lauren Morris; Claire Fletcher; Alexandria Colaco; Mylene Huebecker; Julie Tordo; Nuria Palomar; Giulia Massaro; Els Henckaerts; Simon N Waddington; Frances M Platt; Ahad A Rahim
Journal:  Hum Mol Genet       Date:  2018-09-01       Impact factor: 6.150

9.  Longitudinal MEMRI analysis of brain phenotypes in a mouse model of Niemann-Pick Type C disease.

Authors:  Harikrishna Rallapalli; Benjamin C Darwin; Estefania Toro-Montoya; Jason P Lerch; Daniel H Turnbull
Journal:  Neuroimage       Date:  2020-05-15       Impact factor: 6.556

10.  Plasmid DNA gene therapy of the Niemann-Pick C1 mouse with transferrin receptor-targeted Trojan horse liposomes.

Authors:  Dahai Jiang; Hungyen Lee; William M Pardridge
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.